Cargando…
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
BACKGROUND: In North America the opioid poisoning crisis currently faces the unprecedented challenges brought by the COVID-19 pandemic, further straining people and communities already facing structural and individual vulnerabilities. People with opioid use disorder (OUD) are facing unique challenge...
Autores principales: | Oviedo-Joekes, Eugenia, MacDonald, Scott, Boissonneault, Charles, Harper, Kelli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935000/ https://www.ncbi.nlm.nih.gov/pubmed/33673847 http://dx.doi.org/10.1186/s13011-021-00358-x |
Ejemplares similares
-
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023) -
Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023) -
Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021) -
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023) -
The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)